Table 2

Associations between 18-month intrahepatic fat change and 18-month anthropometric parameters and blood biomarkers changes

	Model 1		Model 2		Model 3
	Beta coefficient	P value	Beta coefficient	P value	Beta coefficient	P value
Anthropometric
∆Weight	0.64	5.3e-25	–		–
∆Waist circumference	0.56	3.7e-19	–		–
∆Systolic BP	0.17	0.01	0.10	0.05	0.07	0.15
∆Diastolic BP	0.28	1.9e-5	0.16	0.005	0.11	0.04
Glycaemic biomarkers
∆Glucose	0.22	0.001	0.11	0.06	0.08	0.15
∆HOMA IR	0.26	8.8e-5	0.13	0.02	0.04	0.49
∆Insulin	0.28	2.9e-5	0.14	0.02	0.03	0.54
Lipid biomarkers
∆Triglycerides	0.38	5.5e-9	0.22	8.1e-5	0.11	0.056
∆Cholesterol	0.08	0.30	0.08	0.16	0.04	0.41
∆HDL	−0.38	7.9e-9	−0.20	0.001	−0.11	0.07
∆LDL	0.04	0.51	0.05	0.40	0.03	0.61
∆TG/HDL ratio	0.40	3.3E-10	0.25	2.0e-5	0.14	0.02
∆Cholesterol/HDL ratio	0.36	2.6e-8	0.24	1.4e-5	0.15	0.007
Liver enzymes and hepatokines
∆ALT	0.32	2.0e-6	0.2	0.001	0.1	0.089
∆AST	0.13	0.049	0.08	0.12	0.07	0.18
∆ALT/AST ratio	0.36	6.2e-8	0.23	9.8e-5	0.10	0.069
∆ALKP	0.03	0.69	−0.001	0.95	−0.008	0.88
∆FGF21	0.26	9.2e-5	0.15	0.01	0.12	0.03
Adipokines and inflammation
∆Chemerin	0.18	0.007	0.13	0.02	0.16	0.001
∆Leptin	0.15	0.03	0.06	0.36	−0.08	0.18
∆hsCRP	0.17	0.02	0.14	0.01	0.09	0.089

Model 1: adjusted for age, sex, baseline IHF% and intervention group.
Model 2: adjusted for age, sex, baseline IHF% intervention group, and 18-month waist circumference change.
Model 3: adjusted for age, sex, baseline IHF%, intervention group and 18-month weight change.
ALKP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; BP, blood pressure; FGF, fibroblast growth factor; HDL, high-density lipoprotein; HOMA IR, homeostatic model assessment of insulin resistance; hsCRP, high sensitivity C reactive protein; LDL, low-density lipoprotein; TG, triglycerides.